CL2018003452A1 - Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. - Google Patents
Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides.Info
- Publication number
- CL2018003452A1 CL2018003452A1 CL2018003452A CL2018003452A CL2018003452A1 CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1 CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A CL2018003452 A CL 2018003452A CL 2018003452 A1 CL2018003452 A1 CL 2018003452A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- semi
- excipients
- cannabinoids
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 229930003827 cannabinoid Natural products 0.000 title abstract 5
- 239000003557 cannabinoid Substances 0.000 title abstract 5
- 239000007788 liquid Substances 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 230000000007 visual effect Effects 0.000 title 1
- 229940065144 cannabinoids Drugs 0.000 abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract 2
- 229950011318 cannabidiol Drugs 0.000 abstract 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920002675 Polyoxyl Polymers 0.000 abstract 1
- 229920000297 Rayon Polymers 0.000 abstract 1
- QXNIBPDSSDVBQP-UHFFFAOYSA-N acetic acid;2-methylpropanoic acid Chemical compound CC(O)=O.CC(C)C(O)=O QXNIBPDSSDVBQP-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN CANNABINOIDES ADECUADAS PARA ADMINISTRACIÓN NASAL. LAS COMPOSICIONES COMPRENDEN LOS CANNABINOIDES MENCIONADOS ANTERIORMENTE Y LOS EXCIPIENTES SELECCIONADOS DE MANERA QUE LAS COMPOSICIONES SON LÍQUIDOS SEMISÓLIDOS O VISCOSOS. EN REALIZACIONES PREFERIDAS, EL CANNABINOIDE ES A9-TETRAHIDROCANNABINOL (THC) O CANNABIDIOL (CBD). LOS EXCIPIENTES SON PREFERIBLEMENTE UNA MEZCLA DE UN VEHÍCULO ACEITOSO (TAL COMO ACEITE DE RICINO O ACETATO DE SACAROSA ISOBUTIRATO) Y UN AGENTE HUMECTANTE / TENSIOACTIVO (COMO OLEOYIL POLIOXILGLICÉRIDOS). LAS COMPOSICIONES PUEDEN COMPRENDER ADEMÁS ESPESANTES (TALES COMO DIÓXIDO DE SILICIO) Y OTROS EXCIPIENTES. SE DESCRIBEN MÉTODOS PARA FABRICAR Y ADMINISTRAR LAS COMPOSICIONES, ASÍ COMO MÉTODOS PARA USAR LAS COMPOSICIONES EN EL TRATAMIENTO DE TRASTORNOS COMÚNMENTE CONOCIDOS POR SER AFECTADOS POR LOS CANNABINOIDES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344486P | 2016-06-02 | 2016-06-02 | |
| US201662426403P | 2016-11-25 | 2016-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003452A1 true CL2018003452A1 (es) | 2019-06-21 |
Family
ID=60478110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003452A CL2018003452A1 (es) | 2016-06-02 | 2018-12-03 | Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170348276A1 (es) |
| EP (1) | EP3478270A4 (es) |
| KR (1) | KR102433459B1 (es) |
| CN (1) | CN109789090A (es) |
| BR (1) | BR112018075073A2 (es) |
| CA (1) | CA3026274A1 (es) |
| CL (1) | CL2018003452A1 (es) |
| CO (1) | CO2018013654A2 (es) |
| MX (1) | MX2018014978A (es) |
| TW (1) | TWI790204B (es) |
| UY (1) | UY37271A (es) |
| WO (1) | WO2017208072A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907823B1 (en) | 2014-11-07 | 2018-03-06 | Eric H. Kuhrts | Water-soluble phytocannabinoid formulations |
| AU2018343256B2 (en) | 2017-09-28 | 2024-09-19 | Zynerba Pharmaceuticals, Inc. | Treatment of Fragile X Syndrome with cannabidiol |
| US20190240148A1 (en) * | 2018-02-07 | 2019-08-08 | Tarukino Holdings, Inc. | Lubricant composition and method for preparing the composition |
| WO2019172876A1 (en) * | 2018-03-05 | 2019-09-12 | Eric Kuhrts | Water-soluble phytocannabinoid formulations |
| US11020357B2 (en) * | 2018-03-19 | 2021-06-01 | Alexandra Yerike | Compound for use in relief of pain and method to produce thereof |
| EP3856172A4 (en) * | 2018-09-28 | 2022-10-05 | Visceral Therapeutics Inc. | PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF GASTROINTESTINAL CONDITIONS |
| US20200170962A1 (en) * | 2018-11-30 | 2020-06-04 | F. Markus Leweke | Nasal cannabidiol compositions |
| EP3893885A4 (en) * | 2018-12-14 | 2022-09-07 | Acerus Biopharma Inc. | ACTIVE ESTER DERIVATIVES OF TESTOSTERONE, COMPOSITIONS AND USES THEREOF |
| MX2021007076A (es) | 2018-12-14 | 2021-08-11 | Zynerba Pharmaceuticals Inc | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. |
| BR102018076973A2 (pt) * | 2018-12-21 | 2020-09-15 | Entourage Participações S.A. | Composição farmacêutica compreendendo extrato de cannabis, produto farmacêutico, processo de preparação da dita composição |
| WO2020142692A1 (en) * | 2019-01-04 | 2020-07-09 | Columbia Care Llc | Topical formulations having cannabinoid |
| WO2020146478A1 (en) * | 2019-01-08 | 2020-07-16 | Replennabis LLC | Cannabinoid formulations for treating alcohol hangover |
| WO2020163866A1 (en) * | 2019-02-08 | 2020-08-13 | Schedule 1 Therapeutics, Inc. | Compositions comprising cannabinoids and methods of use thereof |
| US10993928B2 (en) * | 2019-04-26 | 2021-05-04 | Natural Extraction Systems, LLC | Compositions comprising non-crystalline forms of cannabidiol |
| US20220257560A1 (en) * | 2019-05-23 | 2022-08-18 | India Globalization Capital, Inc. | Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of tourette syndrome |
| CN110433133A (zh) * | 2019-08-19 | 2019-11-12 | 中国人民解放军军事科学院军事医学研究院 | 治疗创伤后应激障碍的大麻二酚鼻用制剂 |
| US20220295853A1 (en) | 2019-08-30 | 2022-09-22 | Sakso | Loaded granules, their process of production and their uses |
| GB2588455B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
| US11419800B2 (en) | 2019-12-06 | 2022-08-23 | JLABS Beauty LLC | Topical compositions containing rose oil and cannabidiol and methods of making and using the same |
| TWI708835B (zh) * | 2020-01-17 | 2020-11-01 | 和協工程股份有限公司 | 緩釋型釋碳凝膠基質及土壤整治方法 |
| CH717205A1 (de) * | 2020-03-11 | 2021-09-15 | Jk Holding Gmbh | Verwendung von Cannabinoiden in Therapie- und Wellnessgeräten. |
| US20210322343A1 (en) * | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
| EP3984522A1 (de) * | 2020-10-19 | 2022-04-20 | Shima Khaki | Zusammensetzung, vorrichtung und verwendung |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| IT202100014909A1 (it) * | 2021-06-08 | 2022-12-08 | Velleja Res S R L | Formulazioni oleose di cannabinoidi |
| CN113304109A (zh) * | 2021-06-08 | 2021-08-27 | 内蒙古大唐药业股份有限公司 | 一种醋柳黄酮固体脂质纳米粒分散液及其制备方法 |
| WO2023028708A1 (en) * | 2021-09-02 | 2023-03-09 | Canopy Growth Corporation | Water-soluble cannabinoid compositions, methods of making and use |
| US11471905B1 (en) | 2021-09-23 | 2022-10-18 | Apackaging Group Llc | All plastic airless pump dispenser |
| EP4186490A1 (en) | 2021-11-29 | 2023-05-31 | Sanity Group GmbH | Kit for preparing a medicament, cannabinoid composition, and preparation method |
| WO2023177675A1 (en) * | 2022-03-15 | 2023-09-21 | Milehigh Repro Solutions, Llc | Methods and systems to reduce injury in treated tissues |
| US12036228B2 (en) | 2022-04-12 | 2024-07-16 | Shackelford Pharma Inc. | Treatment of seizure disorders |
| US11666543B1 (en) * | 2022-07-05 | 2023-06-06 | Poviva Corp. | Pharmaceutical compositions and methods for treating hypertension |
| US11980593B2 (en) | 2022-07-05 | 2024-05-14 | Poviva Corp. | Compositions and methods for treating hypertension |
| WO2024010628A1 (en) * | 2022-07-05 | 2024-01-11 | Poviva Corp | Pharmaceutical compositions and methods for treating hypertension |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| GB0103638D0 (en) * | 2001-02-14 | 2001-03-28 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
| NZ527289A (en) * | 2001-02-14 | 2005-05-27 | Gw Pharma Ltd | Lipophilic medicaments and their administration via mucosal surfaces |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| US8628796B2 (en) * | 2004-12-09 | 2014-01-14 | Insys Therapeutics, Inc. | Room-temperature stable dronabinol formulations |
| WO2007032962A2 (en) * | 2005-09-09 | 2007-03-22 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| AU2012257490A1 (en) * | 2011-05-15 | 2013-12-19 | Acerus Pharmaceuticals Srl | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
-
2017
- 2017-06-02 MX MX2018014978A patent/MX2018014978A/es unknown
- 2017-06-02 EP EP17805945.7A patent/EP3478270A4/en not_active Withdrawn
- 2017-06-02 CN CN201780041815.6A patent/CN109789090A/zh active Pending
- 2017-06-02 UY UY0001037271A patent/UY37271A/es not_active Application Discontinuation
- 2017-06-02 TW TW106118333A patent/TWI790204B/zh active
- 2017-06-02 BR BR112018075073-5A patent/BR112018075073A2/pt not_active Application Discontinuation
- 2017-06-02 WO PCT/IB2017/000759 patent/WO2017208072A2/en unknown
- 2017-06-02 KR KR1020187038219A patent/KR102433459B1/ko active IP Right Grant
- 2017-06-02 US US15/613,116 patent/US20170348276A1/en not_active Abandoned
- 2017-06-02 CA CA3026274A patent/CA3026274A1/en active Pending
-
2018
- 2018-12-03 CL CL2018003452A patent/CL2018003452A1/es unknown
- 2018-12-17 CO CONC2018/0013654A patent/CO2018013654A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY37271A (es) | 2017-11-30 |
| TWI790204B (zh) | 2023-01-21 |
| KR20190034506A (ko) | 2019-04-02 |
| CA3026274A1 (en) | 2017-12-07 |
| EP3478270A2 (en) | 2019-05-08 |
| WO2017208072A3 (en) | 2018-01-11 |
| KR102433459B1 (ko) | 2022-08-17 |
| EP3478270A4 (en) | 2019-11-27 |
| US20170348276A1 (en) | 2017-12-07 |
| TW201801721A (zh) | 2018-01-16 |
| CN109789090A (zh) | 2019-05-21 |
| WO2017208072A2 (en) | 2017-12-07 |
| BR112018075073A2 (pt) | 2019-04-30 |
| CO2018013654A2 (es) | 2019-08-30 |
| MX2018014978A (es) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003452A1 (es) | Formulaciones nasales semi-sólidas y líquidas visuales de cannabinoides. | |
| CL2022000351A1 (es) | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos | |
| CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
| FI2887923T3 (fi) | Polyoksylilipidin tai polyoksylirasvahapon oftalminen formulaatio ja silmätilojen hoito | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| PE20190318A1 (es) | Composicion administrable oralmente | |
| PE20130216A1 (es) | Formulacion topica para un inhibidor de jak | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| NZ731248A (en) | Cannabis extracts and methods of preparing and using same | |
| NZ726746A (en) | Stable cannabinoid formulations | |
| EA201691808A8 (ru) | Кортикостероидные композиции для местного применения | |
| PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
| PE20151663A1 (es) | Composiciones de principios activos farmaceuticos que contienen monoetil eter dietilenglicol u otros derivados de alquilo | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| BR112021002069A2 (pt) | Composição para tratamento capilar, métodos e usos da mesma. | |
| CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| UY36467A (es) | Composición farmacéutica que comprende plasminógeno y usos de este | |
| CO2021005915A2 (es) | Composiciones estables de semaglutida y usos de las mismas | |
| NI201400122A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| BR112015025358A2 (pt) | gotejador ocular e método para administrar gotas de líquido na superfície do olho | |
| AR118823A1 (es) | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa |